Scientists design new drug compound to combat malaria
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.
List view / Grid view
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.
A new vaccine has shown promise at protecting monkeys and mice from COVID-19, its variants and other coronaviruses.
Researchers have found that a metabolite of remdesivir potentially targets a SARS-CoV-2 protein involved in suppressing the host cell's defence response.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
According to new research, the biochip market will grow as a result of the rising demand for personalised medicine.
Scientists have developed a 3D lung-on-a-chip model of the distal lung and alveolar structures, enabling the study of COVID-19.
A summit will be held between the UK and CEPI to raise funds for vaccine research and development in a bid to avert future pandemics.
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
The fat molecule avocatin B, found in avocados, was shown to inhibit VLCAD, an enzyme vital for leukaemia cell metabolism.
Researchers have found that ischemic wounds in pre-clinical models which were treated with a purified exosomal product were healed.
A new study in cell cultures has shown that the sanguinarine plant compound could be used to treat people with triple-negative breast cancer.
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
Researchers have shown in mice that macrophages play a role in controlling blood flow and healing following tissue damage.